Breast Cancer Trial, Recruiting (NCT04902937)

Breast Cancer Trial, Recruiting NCT04902937 Sponsor: University of Jena Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04902937 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with invasive breast cancer that has been confirmed by a tissue biopsy, at various stages but without spread to distant parts of the body.
Your treatment plan includes breast-conserving surgery (keeping most of the breast) with or without chemotherapy or hormone therapy, followed by radiation therapy to the breast and possibly the surrounding lymph node areas.
You are willing and able to give your written consent to take part in the trial.

Who may not be able to join:

You have been diagnosed with DCIS (a very early, non-invasive form of breast cancer) or inflammatory breast cancer (a rare type that causes swelling and redness).
Your breast cancer has come back after a previous treatment (recurrence).
Your cancer has already spread to other parts of the body (such as bones, lungs, or liver).
You have had another type of cancer within the last 10 years before your current breast cancer diagnosis.
You have previously received radiation therapy to any area of the body.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 30 June 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04902937

Sponsor: University of Jena

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

More information: https://clinicaltrials.gov/study/NCT04902937

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with invasive breast cancer that has been confirmed by a tissue biopsy, at various stages but without spread to distant parts of the body.
Your treatment plan includes breast-conserving surgery (keeping most of the breast) with or without chemotherapy or hormone therapy, followed by radiation therapy to the breast and possibly the surrounding lymph node areas.
You are willing and able to give your written consent to take part in the trial.

Who may not be able to join:

You have been diagnosed with DCIS (a very early, non-invasive form of breast cancer) or inflammatory breast cancer (a rare type that causes swelling and redness).
Your breast cancer has come back after a previous treatment (recurrence).
Your cancer has already spread to other parts of the body (such as bones, lungs, or liver).
You have had another type of cancer within the last 10 years before your current breast cancer diagnosis.
You have previously received radiation therapy to any area of the body.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 30 June 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Jena

Registry

ClinicalTrials.gov

Start date

1 July 2021

Est. completion

31 December 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Age-dependent influence of radiotherapy on circulating epithelial tumor cell counts (CETC) and immunophenotype (PBMC).; Longitudinal quantification of CETCs as well as immunophenotype at specific time points during the course of therapy.; Comparison of immunohistochemical parameters of the primary tumor with the immunohistochemical and cytological parameters of CETC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov